Streetbeat News

Products Services

PRTC

PureTech Health has initiated a Phase 2A proof-of-concept trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety. Results are expected by the end of 2023. A Phase 2A trial in patients with postpartum depression is planned to start in 2H 2023.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:15 am

XERS

Xeris Biopharma has announced the dosing of the first participant in a Phase 2 clinical study of its investigational subcutaneous levothyroxine (XP-8121) for patients with hypothyroidism.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:11 am

PTCT

PTC Therapeutics shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC 518 in Huntington's disease patients, showing dose-dependent lowering of huntingtin protein levels in peripheral blood cells.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:10 am

CMMB

Chemomab Therapeutics reports positive data from a secondary analysis of its Phase 2a liver fibrosis trial in NASH patients, showing that treatment with CM-101 improves additional biomarkers of fibrosis and inflammation, reinforcing and extending initial study results.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:08 am

QURE

uniQure announces interim data from Phase I/II trial of AMT-130 in Huntington's disease, showing preserved function and clinical benefits compared to the disease's natural history. The data supports continuing clinical development and pursuing regulatory interactions for late-stage development.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:08 am

BLUE

bluebird bio announced that the FDA has granted priority review for its Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) in patients with sickle cell disease aged 12 years and older with a history of vaso-occlusive events.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:06 am

AZN

PIRS

AstraZeneca has discontinued the Phase 2a trial of Elarekibep (PRS-060/AZD1402) due to new non-clinical safety findings from a 13-week toxicology study. Pieris will review the implications of the data and AstraZeneca's decision before providing further updates.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:04 am

BOTZ

ROBO

Global Predictions has launched PortfolioPilot AI Assistant, a user-friendly platform providing personalized investment guidance. The tool aims to replace traditional financial advisors and democratize access to professional insights and tools. The company has over 11,000 active users with $5.8 billion of assets on the platform.

Portfolio Pulse from Anusuya Lahiri

June 21, 2023 | 11:03 am

AMZN

INDA

Amazon has introduced a doorstep cash load option for Amazon Pay in India, allowing customers to add cash to their Amazon Pay balance at their doorstep. The service accepts ₹2,000 notes and aims to provide a convenient way for users to top up their accounts.

Portfolio Pulse from Charles Gross

June 21, 2023 | 10:42 am

TFX

Teleflex Incorporated (NYSE:TFX) has announced a partnership with Shenzhen Insighters Medical Technology Co., Ltd. to become the exclusive U.S. distributor of the Insighters Video Laryngoscope system.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 10:34 am